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PATHOS is a phase II/III randomized controlled trial (RCT) of risk-stratified, reduced
intensity adjuvant treatment in patients undergoing transoral surgery (TOS) for human
papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC). The
study opened in the UK in October 2015 and, after successful recruitment into the
phase II, transitioned into phase III in the autumn of 2018. PATHOS aims to establish
whether the de-intensification of adjuvant treatment in patients with favorable prognosis
HPV-positive OPSCC will confer improved swallowing outcomes, whilst maintaining high
rates of cure. In this article, we will outline the rationale for the study and how it aims to
answer fundamentally important questions about the safety, effectiveness and functional
outcomes of minimally invasive TOS techniques followed by adjuvant radiotherapy (RT)
or chemo-radiotherapy (CRT) in this patient population.
Keywords: HPV-related head and neck squamous cell carcinoma, PATHOS, deintensification, transoral surgery,
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INTRODUCTION
PATHOS is a phase II/III randomized controlled trial (RCT) of risk-stratified, reduced intensity
adjuvant treatment in patients undergoing transoral surgery (TOS) for human papillomavirus
(HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC). The study opened in the UK
in October 2015 and, after successful recruitment into the phase II with a primary objective of
swallowing function at 12 months (MD Anderson Dysphagia Inventory, MDADI), transitioned
into phase III in the autumn of 2018 with co-primary endpoints of overall survival and MDADI
at 12 months. PATHOS aims to establish whether the de-intensification of adjuvant treatment
in patients with favorable prognosis HPV-positive OPSCC will confer improved swallowing
outcomes, whilst maintaining high rates of cure. In this article, we will outline the rationale for the
study and how it aims to answer fundamentally important questions about the safety, effectiveness
and functional outcomes of minimally invasive TOS techniques followed by adjuvant radiotherapy
(RT) or chemo-radiotherapy (CRT) in this patient population.
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EXPLANATION OF TRIAL RATIONALE
Improved Prognosis of HPV-Positive
Oropharyngeal Carcinoma
OPSCC is increasing in incidence worldwide due to infection
with HPV, predominantly genotype 16. Mehanna et al. reported
that 70% of OPSCC currently diagnosed in Europe are HPV-
positive (1) although areas of Europe outside of the UK and
Northern Europe were under-represented in this study and there
is a lack of data for other countries, e.g., in Eastern Europe.
Patients with HPV-positive OPSCC have a significantly better
prognosis, with a 58% reduction in the risk of death compared
to patients with HPV-negative OPSCC (2). Patients tend to be
younger and fitter and have 3 year overall survival (OS) rates
in the order of 90%, although rates vary with stage and are
influenced by other factors, including smoking history (2–4).
This improved prognosis is reflected in the new TNM staging
system, TNM8, which separates HPV-positive OPSCC from
HPV-negative OPSCC in its prognostic staging groups (5). HPV-
positive OPSCC appears to be more radiosensitive than HPV-
negative OPSCC and HPV positive cell lines have increased
radiosensitivity in vitro as a result of impaired DNA repair
mechanisms (6, 7). Patients with HPV-positive disease have
a higher response rate to radiotherapy alone (8), (induction)
chemotherapy (9), and chemo-radiotherapy (9), compared to
patients with HPV-negative disease.
Current treatment protocols for the management of OPSCC
do not take HPV status into account and standard treatments,
outside of clinical trials, are similar irrespective of HPV
status. This is wholly appropriate until clinical trials prove
that treatment may be modified in patients with HPV-
positive disease. The importance of not modifying treatment
prematurely is demonstrated by the recently published RTOG
1016 (10) and De-Escalate HPV (11) studies both of which
reported superior outcomes with standard of care Cisplatin-
based CRT compared to Cetuximab and radiotherapy in
patients with HPV-positive OPSCC. Definitive results from
other de-intensification/protocol modification trials in patients
undergoing primary non-surgical management for HPV-positive
oropharyngeal cancer are awaited. The importance of waiting for
such data is reflected in the recommendations of The National
Institute for Clinical Excellence (NICE). NICE is a UK based
organization which provides advice and guidance concerning
the improvement of health and social care. NICE guidelines on
management of patients with cancers of the upper aerodigestive
tract1, which were updated in 2016, have a section on De-
intensification of treatment in HPV-positive OPSCC which
states: “Do not offer de-intensification of curative treatment to
people with HPV-positive cancer of the oropharynx, unless it is
part of a clinical trial.” Carefully planned and well-monitored
studies are therefore a fundamental part of the effort to improve
future treatments for HPV-positive OPSCC. This is reinforced
by the recently published ASCO provisional clinical opinion by
Adelstein et al. (12) which concludes that whilst the prognostic
ability of the 8th edition of the American Joint Committee on
1www.nice.org.uk/guidance/ng36/chapter/recommendations/hpvrelated-disease
Cancer Staging System is considered to be strong and reflective
of the current outcomes of treatment for HPV-positive OPSCC
“careful study and the analysis of well-designed clinical trials”
are mandatory prior to altering current standard practice in this
group of patients.
Transoral Surgery for Oropharyngeal
Cancer: A New Treatment Paradigm
Transoral Surgery (TOS), including non-endoscopic methods
such as the Huet procedure ie, TOS with a monopolar cautery,
as well as endoscopic-assisted transoral surgery—Transoral Laser
Microsurgery (TLM) or Transoral Robotic Surgery (TORS)—
are minimally invasive surgical procedures, usually performed
with a neck dissection, which have become more widely adopted
for the treatment of OPSCC over the last 10–15 years (13–
15). These techniques have the potential to excise OPSCCs
with significantly less functional morbidity (16) compared to
traditional, open access surgical techniques (17). Two systematic
reviews and a meta-analysis (18–20) have reported similar
oncological outcomes from TOS compared to primary RT/CRT,
albeit with a different profile of adverse events.
The ORATOR trial (NCT01590355) (21) presented earlier this
year is the first study we are aware of which randomized patients
with OPSCC to either trans-oral robotic surgery or primary
radiotherapy ± concurrent chemotherapy. Between 2012 and
2017, 68 patients were randomized, 34 in each arm. P16 status
was positive in 88% of patients. The results have only been
published in abstract form so far after a median follow-up of
27 months. MDADI scores were statistically superior in the
radiotherapy group (P = 0.042), although did not meet the
definition of a Clinically Meaningful Difference (CMD). For all
other QOL of life metrics, outcomes were similar at 12 months
and overall and progression-free survival outcomes were also
similar. We await the comprehensive results of this small study
with interest, as well as data on the proportion of patients who
received adjuvant treatment following TORS. It is important to
highlight that the question of de-escalation of adjuvant therapy
was not addressed in this study (unlike PATHOS).
Adjuvant (Post-Operative) Treatment for
OPSCC
Surgery for OPSCC is followed, in most cases, by adjuvant
treatment with either post-operative radiotherapy (PORT) or
post-operative chemo-radiotherapy (POCRT). In reality, the
optimal adjuvant treatment following TOS is not well-defined,
particularly in the context of HPV-positive OPSCC.
Standard post-operative radiotherapy (PORT) protocols are
based on the results of studies such as RTOG 73-03 (22) (reported
over 30 years ago) that demonstrated improved local control in
locally advanced head and neck cancers following PORT (23). A
subsequent randomized study (24) explored the optimum dose
for PORT and recommended a minimum dose of 57.6Gy to
the operative primary tumor bed and involved lymph nodes
areas, with a dose of 63Gy in 1.8Gy fractions limited to sites
at higher risk, particularly areas of extracapsular spread (ECS).
Updated long term data from this study did not, however, show
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a dose response relationship above doses of 57Gy in patients
with good prognosis disease (based on a cumulative points score)
whereas poor prognosis patients required 60–63Gy (25). Not
surprisingly there is significant variation in practice; in the UK,
most centers recommend a dose of 60Gy in 30 fractions over 6
weeks for the majority of patients, with an optional boost to high
risk areas (ECS and/or positive margins) up to 66Gy (26). It is
important to appreciate that the historical studies, upon which
the doses of PORT we prescribe today are based, would have
had a relatively low proportion of patients with HPV-positive
OPSCC, because of the lower prevalence of HPV in OPSCC at
the time and also the inclusion in these studies of multiple head
and neck cancer subtypes, not only OPSCC. This observation is
also true when considering the use of POCRT. Current practice
has been informed by the results of two international studies
(EORTC 22931/RTOG 9501). Pooled results from these studies
(27) demonstrated improved overall survival (OS) in patients
with positive (or “involved”) surgical resection margins around
the primary tumor and/or presence of ECS in nodal disease of the
neck and these pathological features are now widely used criteria
for POCRT. These studies included patients with squamous cell
cancers from a variety of head and neck sub-sites recruited
between 1994 and 2000 and, based on HPV prevalence rates at
that time (1), we estimate that <100 patients (∼13% of study
cohorts) recruited to these studies would have had HPV-positive
OPSCC. Consequently, it is unclear how relevant these results are
to patients with HPV-positive OPSCC.
There is a large body of evidence demonstrating an excess
of acute and late toxicity attributable to adjuvant treatment
following TOS. In a prospective cohort study of 111 patients
(28), the 13 who had TORS alone did not require a gastrostomy
tube and had significantly higher eating scores at 3 and 6
months compared to those who received adjuvant treatment.
The 60% (67/111) who received POCRT had consistently worse
overall QOL scores until 6 months after completion of treatment.
Gastrostomy tube use was doubled by adjuvant treatment in the
largest TLM series (13), including 204 patients, from 17 to 33%.
Nineteen percent were still dependent upon a gastrostomy tube
a year after treatment. In 66 OPSCC patients treated with TORS
(32), 97% were managing an oral diet a month after surgery, but
subsequently 27% (18/66) required a gastrostomy tube during
their adjuvant therapy and three (4.5%) remained dependent
upon a tube for more than 2 years after treatment. A similar
outcome was observed in 81 patients treated with TORS (33). All
patients were discharged postoperatively on a full oral diet, but
13 (16%) required gastrostomy tube placement during adjuvant
treatment. Five patients were still dependent upon a tube over a
year later. Factors which predict for tube dependency include age
(>55 years) and the extent of TORS resection. A high T stage
(pT3/pT4) predicted the need for permanent dependency upon
tube feeding.
The addition of chemotherapy to adjuvant radiotherapy
predicts for worse functional outcomes compared to adjuvant
radiotherapy alone. In 38 OPSCC patients, speech, diet and
eating scores at 6 and 12 months after treatment were
significantly higher following TORS without adjuvant treatment
vs. TORS followed by PORT. Scores following POCRT were
worse again (34). In addition to the above, a systematic review
of TORS for OPSCC demonstrated a significant deterioration
for a range of swallowing outcome measures in those who had
chemotherapy in addition to adjuvant radiotherapy (35).
Rationale for De-Intensification
It is known that toxicities are strongly linked to the dose of
radiotherapy (RT) received by the normal tissues. Severe late
toxicities have been reported in 43% of patients after treatment
with primary CRT, albeit in the pre-IMRT era, and toxicity of
this magnitude can last a lifetime (36). The key late toxicity
which has the greatest impact on QoL is dysphagia (difficulty
swallowing) (37). Dysphagia is an independent predictor of
poor QoL and correlates with the mean dose of RT received
by swallow-related organs, especially the superior pharyngeal
constrictor muscles (PCM) and the supraglottic larynx (38).
Chronic dysphagia is a complex problem; one study looked
at a consecutive series of patients who had all been referred
for modified barium swallow for the investigation of chronic
dysphagia up to 5 years following definitive RT/CCRT for head
and neck cancer. The majority of cases were oropharyngeal.
Eighty six percent (25/29) of these patients suffered repeated
episodes of aspiration pneumonia with half of these cases
warranting hospitalization (39).
In view of the fact that HPV positive OPSCC patients are
younger, and more likely to survive for many years following
their diagnosis and treatment, efforts to explore the potential
of de-intensified treatment strategies in order to reduce long-
term toxicities are at the forefront of current head and neck
oncology research (see Table 1 for a summary). Despite the
negative results from two phase III studies which have substituted
Cisplatin for Cetuximab (10, 11), early results from phase II
studies evaluating other strategies for toxicity reduction have
reported promising results.
Two trials have explored the potential for reduced dose
radiotherapy following response to induction chemotherapy.
ECOG 1308 (29) was a single arm phase II study which showed
promising outcomes with reduced dose radiotherapy (54Gy in
27 fractions and Cetuximab) in 80 patients with a complete
response to 3 cycles of induction chemotherapy (TPF: Docetaxel,
Cisplatin and 5-FU). Although 2 year Progression Free Survival
(PFS) of 80% (95% CI: 65-89) was lower than expected, post-
hoc analysis suggested extremely good outcomes (2 year PFS and
OS of 96% [95% CI: 76-99]) in favorable-risk patients (TNM7:
T1-3 N1-N2b, <10 pack/year smoking history). Another single
arm phase II study of 44 patients with stage I-III (TNM8) HPV-
positive OPSCC (30) gave 54Gy in 27 fractions of radiotherapy
to the primary tumor and involved nodes and 43Gy to the
prophylactically treated uninvolved nodes, with weekly Paclitaxel
chemotherapy in patients who had a complete or partial
response to 2 cycles of induction chemotherapy (Carboplatin
and Paclitaxel). The trial demonstrated a PFS rate of 92% (95%
CI 77–97%). This compared favorably with historical studies,
in addition to a reduced toxicity profile. Whilst the results of
small, non-randomized studies must be interpreted with caution,
they suggest that the strategy of reduced dose radiotherapy
after induction chemotherapy warrants further evaluation in
larger studies.
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TABLE 1 | Summary of completed relevant trials mentioned in this review.
Trial reference Type of trial Patient numbers Topic Conclusion
RTOG 1016 (10) Randomized Phase 3 849 Cisplatin/RT vs. Cetuximab/RT Superior outcomes in Cisplatin/RT group
DeEscalate HPV (11) Randomized Phase 3 334 Cisplatin/RT vs. Cetux/RT Superior outcomes in Cisplatin/RT group
ORATOR (21) Randomized Phase 3 68 TORS vs. primary RT ± adjuvant treatment At 27 mths follow up superior outcomes in
primary RT group
Sethia et al. (28) Prospective cohort 111 TORS ± POCRT POCRT reduces QoL up to 6 months
post-treatment
ECOG 1308 (29) Single arm phase 2 80 3 × IDC with cCR 54Gy/27F + Cetux Good outcomes in favorable risk groups
Chen et al. (30) Single arm phase 2 44 2 × IDC with cCR or cPR 54Gy/27F +
weekly pac
Good outcomes and reduced toxicity
Chera et al. (31) Single arm phase 2 44 60Gy/30F with weekly 30 mg/m2 cis Comparable oncological control and
reduced toxicity
Other studies have investigated the role of reduced dose
radiotherapy in HPV-positive OPSCC, without prior use of
induction therapy. In one prospective single-arm phase II study
44 patients with stage I-II (TNM7) HPV-positive OPSCC and
a minimal smoking history were treated with reduced dose
IMRT and reduced dose concomitant weekly cisplatin (31,
40). In total 43 patients underwent the surgery and were
included in the analysis. Biopsies of tumor sites following
treatment demonstrated complete pathological response rate of
98% (40/41) at the primary site (2 patients were T0) and 84%
(33/39) in the neck nodes. The biopsy-positive primary site was
resected and no viable tumor found. Treatment was associated
comparable oncological control and reduced toxicity rates when
compared with contemporary studies (e.g., PARADIGM) where
patients received 70Gy of radiation.
The NRG HN-002 study uses a lower dose of radiotherapy
to treat good prognosis HPV-positive OPSCC. Patients were
randomized to receive reduced dose IMRT, 60Gy in 30 fractions
over 6 weeks with concurrent weekly Cisplatin (40 mg/m2) or
moderately accelerated reduced dose IMRT alone, 60Gy in 30
fractions over 5 weeks. The study is currently in follow-up.
The possibility that TOS followed by reduced intensity
PORT or POCRT may be used to reduce long term
functional morbidity in patients with favorable prognosis
HPV-positive OPSCC is currently being tested in the
PATHOS study (ClinicalTrials.gov NCT02215265), a UK
and European prospective, phase III, randomized controlled trial
(RCT) (41).
TRIAL DESIGN AND JUSTIFICATION
The PATHOS (Postoperative Adjuvant Treatment for Human
Papillomavirus (HPV)-positive Tumors) study, aims to
demonstrate that risk-stratified de-intensification of adjuvant
treatment maintains high survival and low recurrence rates in
patients with HPV-positive OPSCC, but improves long term
swallowing function (Figure 1).
Multiple studies have shown 50–60Gy to be a critical dose
range concerning the risk of long term dysphagia when delivered
to the pharyngeal musculature (42–44). A systemic review in
2017 (45) found that prognostic factors consistently associated
with a risk of feeding tube dependency both short term and over
6months after treatment included the dose received to the larynx,
superior and inferior PCMs and the contralateral parotid gland.
Threshold values for tube dependency beyond 6 months were a
mean dose (Dmean) of 50.7Gy to the larynx and inferior PCMs.
This is supported by normal tissue complication probability
(NTCP) models for swallowing endpoints including a steep rise
in the NTCP curve when the mean dose to PCMs reaches 50–
55Gy (46). No threshold value was found for the contralateral
parotid gland. In an overview of studies characterizing the
effect of radiation on normal tissues in relation to the quality
of life of head and neck cancer patients (47), dose thresholds
to normal tissue structures were recommended on the basis
of numerous studies which looked at both the physiology of
xerostomia and dysphagia—the two symptoms which have the
most negative impact on QoL of these patients. These included
keeping a Dmean below 26Gy to the parotid gland and 39Gy to
the contralateral submandibular gland. Generally a mean dose
threshold of 50–60Gy was reported for the multiple pairs of
muscles involved in swallowing. A dose less than this resulted
in only very minor risk of aspiration. A recommendation was
therefore made to keep the mean dose to the PCMs below 50Gy
and <20Gy to the larynx. The Eisbruch Group (42) supported
this with data showing when superior PCMs receive 56Gy there
is a 25% risk of aspiration detected by VF, when they receive 63Gy
this increases to 50%. Reducing post-operative radiotherapy
(PORT) from 60 to 50Gy may therefore significantly reduce
long term swallowing complications following treatment. The
reduced dose of 50Gy being tested in Group B patients was
recommended by the National Cancer Institute (NCI) Head and
Neck cancer steering committee’s clinical trials planning meeting
in the postoperative setting following TORS of pharyngeal
cancers (48). The same dose has been tested in the ECOG
3311 study (NCT01898494), a phase II US RCT which has
also evaluated the role of reduced dose PORT in patients
with “intermediate risk” pathological risk factors after TOS,
with progression free survival (PFS) as its primary endpoint.
ECOG 3311 has completed recruitment and is currently
in follow-up.
In addition to PORT, adjuvant chemotherapy (POCRT)
following TOS for OPSCC is also a significant factor influencing
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FIGURE 1 | Patients with T1-3 N0-N2b (TNM7) HPV positive OPSCC undergo TOS and neck dissection before being stratified into risk groups based upon their
pathology. Randomization takes place within the intermediate (Group B) and high risk (Group C) groups. Patients in Group B [T3/N2, PNI, vascular invasion (VI)] are
randomized between the control arm of 60Gy in 30 fractions over 6 weeks of PORT and the test arm of 50Gy in 25 fractions over 5 weeks. Patients in Group C
(involved <1mm margins and/or ECS) are randomized between a control arm of POCRT, 60Gy in 30 fractions over 6 weeks with concurrent Cisplatin and the test
arm of PORT alone, 60Gy in 30 fractions over 6 weeks. There is an option to boost high-risk sub-volumes to 66Gy in 30# over 6 weeks in Group C patients. The
co-primary end points are patient-reported swallowing function (MD Anderson Dysphagia Inventory score) 12 months after treatment and overall survival. Secondary
outputs include loco-regional control and quality of life.
swallowing outcomes (13). Historically, POCRT has been advised
for patients with tumors demonstrating high risk features
including involved margins and/or ECS. This advice is based
upon the combined results of studies such as EORTC 22931 and
RTOG 9501 (27) which, as mentioned earlier, are not wholly
representative of the HPV-positive demographic. Indeed, when
there is a lack of soft tissue deposits, there is a lack of clarity
in the literature to date as to whether ECS is prognostic in the
context of HPV-positive OPSCC. Ultimately, there is a limited
amount of prospective data on the prognostic nature of ECS
and whether or not chemotherapy in addition to radiotherapy
impacts upon outcomes. Some retrospective studies show ECS
to be a poor predictor of recurrence (49, 50) whilst other
retrospective studies support an association between ECS and
inferior survival (51, 52). Furthermore, retrospective studies
have not demonstrated any overall survival benefit with POCRT
compared to PORT alone following TLM in patients with high-
risk pathological features (53). In view of the significant increase
in toxicity due to the addition of chemotherapy (including a
2% increase in treatment-related mortality), it is of upmost
importance we are able to justify the inclusion of chemotherapy
in adjuvant treatment regimes in the context of HPV-positive
OPSCC. By randomizing patients with ECS to PORT vs. POCRT,
PATHOS will provide much needed, important prospective data
on this issue.
With the inclusion of TORS and TLM, PATHOS will add
to another area where evidence for adjuvant treatment and
functional outcomes is lacking. Open surgery plus adjuvant RT
are associated with worse functional outcomes compared to
primary chemo/RT but swallowing outcomes following transoral
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techniques for OPSCC are not well-reported. A systemic review
and meta-analysis of over 500 patients in 17 retrospective
studies treated with TORS concluded that treatment with TORS
had a good rate of oncological control as well as a positive
impact upon QoL and long term swallowing function (54).
Two published retrospective series of patients treated with TLM
and any appropriate adjuvant treatment, have demonstrated
oncological control equivalent to non-surgical management in
addition to good swallowing function outcomes when compared
to non-surgical series. Rich et al. (53) published a series of 84
patients with stage III or IV OPSCC treated primarily with TLM.
Eighty two percent were HPV positive and 92% received adjuvant
treatment. At a minimal follow up of 2 years, disease specific
survival at 2 years was 96% and at last follow up, 81% had
acceptable swallowing function (normal–mild dysphagia). 3.4%
remained dependent upon a gastrostomy tube for feeding. The
second series (14) was larger and reported on 153 patients, of
which 66% were HPV positive. OS at 3 years was 84.5% and
tube dependency at 1 year was 1.3%. Both series concluded
that TLM offered equivalent oncological control to non-surgical
options in this setting, and demonstrated superior swallowing
function outcomes when compared to published non-surgical
data. PATHOS will allow us an opportunity to prospectively
investigate whether we can build upon these positive outcomes
by including a similar demographic of patient cohorts who are
treated following TORS with de-escalated adjuvant therapy. To
date, apart from the early data from ORATOR, there has not
been any prospective randomized data on functional and cancer-
specific outcomes in OPSCC treated with TLM or TORS.
TRIAL OUTCOME MEASURES
In order to inform research priorities, two head and neck patient
focus groups were consulted and strongly agreed that there
was a lack of research concerning swallowing outcomes. They
particularly highlighted the need for focusing on the prevention
of dysphagia. A PATHOS patient engagement group has been
formed, including 5 patients who have had transoral resection
for OPSCC either with or without adjuvant treatment. They
all agreed that the adjuvant treatment was much harder to get
through compared to the initial transoral resection, and was the
source of the majority of significant and long term side effects.
The primary outcome of the phase 2 and co-primary endpoint
of the phase III is long term swallowing function, assessed
by the MDADI at 12 months. This particular time point
was chosen as the aim is to analyze long term swallowing
outcomes. Longitudinal data (55) demonstrates that the majority
of functional recovery is seen by 12 months with minimal
amounts of recovery seen between 12 and 24 months. MDADI
is psychometrically validated, sensitive to longitudinal changes
and its trajectories follow expected patterns in distinguishing
between different cancer treatment regimens (56, 57). It is widely
used in clinical practice and has been included as an outcome
measure in a range of UK and international trials such as ECOG
3311 (NCT01898494), NRG HN002 (NCT02254278), DARS
(58), Best-of (NCT02984410), De-Escalate (11), and TORPEdO
(NCT03561220). A 10 point difference between groups in the
MDADI score differentiates aspirators from non-aspirators,
tube-dependent from oral eaters and clinically distinct diet levels
(59) and has been set as the Minimum Clinically Important
Difference (MCID) for the study.
The best objective measure of swallowing function is
videofluoroscopy (VF) as it offers a real time visualization of
the oropharyngeal swallow, displaying the swallowing process
from the lips to the upper esophageal tract. VF detects dysphagia
endpoints which are clinically significant and may not otherwise
be picked up on patient reported outcomes, such as aspiration.
The recovery of swallowing after head and neck cancer treatment
is multifaceted and differs both between clinical tests and
clinician and patient-reported outcomes. No single measure of
swallow function can replace another and the pathway of each
assessment can alter throughout survivorship. With this in mind,
as well as performing VF, PATHOS introduces a novel panel
of swallowing assessments which the trial hopes to validate.
The panel was developed in collaboration with internationally
recognized experts in swallowing and with a wide range of
experience of multi-center studies. To permit comparisons with
a related trial, DARS (58), the swallowing panel has been adopted
by the two studies. The panel includes the Performance Status
Scale–Head and Neck (PSS-HN) (60); a 3-item clinician assessed
measure of functional performance based on patient interviews.
It is quick and inexpensive and has been adopted by HANA, the
UK Head and Neck Audit. The Water Swallow Test (WST) is
included which is quick and inexpensive, offering an effective
way to monitor overall swallowing performance. Finally, the
panel also includes the EORTC QLQ C30 (61) and HN35
(62) questionnaires which incorporate psychological, social,
occupational and physical well-being to form amultidimensional
assessment of the overall health-related quality of life of a patient.
PATHOS was designed as a Phase II study that would roll
seamlessly into a Phase III. The Phase II was originally designed
to prove feasibility of recruitment and superiority of swallowing
function with deintensification with the Phase III being designed
to prove non-inferiority of overall survival. Initially the Phase
II stage of the study was funded by Cancer Research UK. As
planned, once we proved feasibility of recruitment we applied
for funding for the Phase III to prevent a hiatus in recruitment
whilst we waited for the Phase II swallowing data to mature. The
funding committee approved the Phase III funding but specified
that the swallowing outcome should be moved to a co-primary
endpoint of the Phase III. Consequently the trial is now in Phase
III with the following design. Assuming:
1. Recruitment from Phase II and III takes 6.5 years
2. Follow up continues for a further 4 years
3. Overall survival in the control arms is 92% at 3 years (13)
4. Common exponential drop-out rate of 0.02
it is calculated that 574 patients and 94 events will be required
to demonstrate that the 3 year overall survival is not worse than
87% [a 5% non-inferiority margin from the 92% in the control
arm (equivalent to a hazard ratio of 1.795)], with power 80% and
one-sided alpha of 5% [calculations done using nQuery+ nTerim
version 3.0 (63)]. For the co-primary endpoint of swallowing
function, with 574 patients randomized, to find a difference of
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10 pts (58) in MDADI with SD = 15, alpha = 0.05 two sided,
we will have 99.99% power. So even if MDADI is completely
independent of OS, the overall power for the co-primary will
be 80%. Recruitment will continue until 574 patients have been
randomized into Group C. We predict that this will be when
∼1,100 patients have been recruited prior to surgery. We predict
that fewer patients will be recruited into Group B (n = 210)
but we intend to combine data with the ECOG 3311 trial (n =
377, estimated to complete in 2023, randomizing patients with
“intermediate risk” pathology to 60Gy in 30 fractions or 50Gy
in 25 fractions of RT, primary endpoint PFS), which should be
sufficient to analyse the non-inferiority of OS in Group B in a
pooled analysis. In order to assess the validity of pooling the
data from the two trials, the OS in the control groups from the
two trials will be compared prior to analysis. We predict that
recruitment will continue until late 2022 with follow up for 4
years after that.
ADDITIONAL BENEFITS
PATHOS is the first UK study of post-operative IMRT for head
and neck cancer and so presents an excellent opportunity to
develop radiotherapy treatment quality assurance (RTTQA) in
this area. Following discussion with the NCRI RTQQA group,
a comprehensive RT-QA protocol has been developed for use
within PATHOS. An additional novel aspect of PATHOS will
involve the production of an atlas to guide the outlining of
swallowing structures. Dose/volume data for the swallowing
structures will be collected and for the first time compared to
toxicity outcomes prospectively in a randomized trial. There is an
ever increasing uptake of transoral surgical practice in the UK but
as yet there is no current standardized practice for the treatment
of OPSCC. PATHOS is a unique opportunity to standardize
trans-oral techniques and establish surgical quality assurance
(QA). Surgical QA and quality control (QC) will therefore
be defined within a surgical guidance document developed
for the PATHOS protocol. Finally, pathological reporting of
HPV-positive OPSCC has not been standardized in the UK
and PATHOS represents an opportunity to develop this. In
addition, a National Cancer Institute Head and Neck Cancer
Steering Committee Clinical Trials Planning Meeting on TORS
of pharyngeal surgery in 2011 (48) requested the traditional
pathological risk factors be re-evaluated in the context of
HPV-positive disease. The PATHOS team have developed a
pathology guidance document that clearly defines clear and close
margins, and the need for marginal biopsies as part of the
TLM procedure.
INTERNATIONAL COLLABORATION
PATHOS is a Cancer Research UK (CRUK) funded study which
initially opened in the UK as a phase II study in October
2015 and has recruited well, with 259 patients entering the
study by 01/2019. With further support from CRUK, the study
transitioned seamlessly into the phase III in October 2018, aiming
to open across international sites in Europe and further afield,
including Australia and the US. In Europe, the study will be
conducted in collaboration with the European Organization for
the Research and Treatment of Cancer (EORTC) Head and
Neck group, as well as other international partners in France
and elsewhere. This collaborative grouping will work together to
recruit the ∼1,100 patients required by 2022. If this is achieved,
PATHOS will be a potentially practice changing trial, which
could establish TOS followed by reduced intensity RRT/CRT as
a standard of care for future patients with transorally resectable
HPV positive OPSCC.
CONCLUSION
The highly attractive prospect that treatment protocols can
be de-intensified to minimize long term toxicity in patients
with favorable prognosis OPSCC must be fully evaluated in
prospective, randomized clinical trials before being adopted into
routine care. PATHOS is an international collaborative trial
which will help define the role of TOS followed by reduced
intensity adjuvant RT/CRT in future treatment paradigms
for this disease. Whilst the setting up of a trial of this
magnitude and breadth is not a trivial undertaking, it will
only be through continuous establishment of randomized
controlled trials such as this that fundamental clinical questions
can be answered in a safe and scientific manner in order
to ultimately improve patient care and the quality of life
experienced after treatment.
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